Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xiongdan Powder (Bear Bile Powder) is a traditional Chinese medicine derived from the dried bile of the black bear (*Ursus thibetanus*) or brown bear (*Ursus arctos*). It is approved in China for the treatment of heat-related convulsions, red swollen eyes, and sore throat. The primary active components of Xiongdan Powder are bile acids, specifically tauroursodeoxycholic acid (TUDCA), ursodeoxycholic acid (UDCA), and chenodeoxycholic acid (CDCA). These active ingredients act as agonists of the G-protein coupled bile acid receptor 1 (GPBAR1/TGR5) and the farnesoid X receptor (FXR), which regulate bile acid homeostasis, lipid metabolism, and inflammatory pathways. Chengdu Yongkon Pharmacy is a key developer and manufacturer of this product.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xiongdan Powder.